KRAS and cancer: Heterogeneity and biological plasticity are typical features of tumours, which limit the initial therapy response rate and allow for the early adaptation to clinical treatment, thereby representing a critical challenge of curation in various cancer types, including KRAS‐mutant lung cancer.